ADMA Biologics director buys 7,000 shares at $15.39, posts 28.8% net margin
ADMA Biologics director Steve Elms purchased 7,000 shares at $15.39 on March 6, raising his stake to 2,045,730 shares and signaling insider confidence. The company reports a 28.8% net margin, 37.5% return on equity and maintains a 0.17 debt-to-equity ratio with a 6.71 current ratio.
1. Insider Share Acquisition
On March 6, director Steve Elms purchased 7,000 shares of ADMA Biologics at $15.39 each, increasing his total holdings to 2,045,730 shares. This transaction underscores executive confidence in the company’s prospects and aligns insider interests with shareholder value.
2. Strong Profitability Metrics
ADMA Biologics reported a net margin of 28.8%, a return on equity of 37.52% and a return on assets of 27.87%. These figures highlight efficient operations and profitability levels that exceed many peers in the specialty plasma-derived products sector.
3. Conservative Leverage and Robust Liquidity
The company maintains a low debt-to-equity ratio of 0.17 and a current ratio of 6.71, indicating minimal leverage and ample liquidity. This conservative capital structure positions ADMA to fund operations and absorb potential market fluctuations without significant financial strain.
4. Valuation Ratios and Ownership Structure
ADMA trades at a price-to-earnings ratio of 24.45, a price-to-sales ratio of 7.05 and an enterprise-value-to-sales ratio of 7.03, with an enterprise-value-to-operating-cash-flow ratio of 71.19. Institutional investors hold 75.7% of shares, while insiders own 3.7%, reflecting strong external confidence and moderate insider alignment.